Valeant subpoenaed by U.S. prosecutors; shares drop
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St rises as chip rally offsets renewed Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices slide over 1% as US-Iran conflict clouds Hormuz reopening
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Valeant's (VRX) Buy Rating Reiterated at BofA/Merrill Lynch
October 15, 2015 10:12 AM EDTBofA/Merrill Lynch reiterated a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $290. Analyst Sumant S. Kulkarni said while volatility is expected, due to overly conservative DCF scenarios on pricing, weakness could present a "particularly good opportunity."
BofA/Merrill... More
